Published in Clin Pharmacol on September 21, 2016
Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients | NCT02532764
Bactericidal and Fungicidal Activity of N-Chlorotaurine Is Enhanced in Cystic Fibrosis Sputum Medium. Antimicrob Agents Chemother (2017) 0.77
Recent Insights into the Role of Unfolded Protein Response in ER Stress in Health and Disease. Front Cell Dev Biol (2017) 0.77
Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis. Pathogens (2017) 0.75
Personalized or Precision Medicine? The Example of Cystic Fibrosis. Front Pharmacol (2017) 0.75
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (1989) 40.22
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell (1990) 9.21
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature (1992) 8.47
Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell (1998) 6.72
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell (1993) 6.25
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science (1991) 5.82
Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science (1985) 5.81
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A (2009) 5.72
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature (1992) 5.45
Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat (2002) 5.43
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med (2003) 4.43
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet (2008) 4.35
Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest (2005) 4.19
Chloride impermeability in cystic fibrosis. Nature (1983) 3.98
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A (2011) 3.87
Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med (1981) 3.85
Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med (1996) 3.82
Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell (1991) 3.75
The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature (2006) 3.66
CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol (2006) 3.60
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol (2006) 3.59
Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J (2003) 3.35
CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature (2005) 3.24
Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science (1991) 3.12
Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem (1996) 3.07
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2011) 2.84
Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones (1996) 2.80
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A (2002) 2.71
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol (2009) 2.70
Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol (2000) 2.48
Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science (2004) 2.39
Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med (Berl) (2002) 2.34
Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet (2008) 2.33
In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest (1997) 2.29
Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol (2010) 2.29
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med (2014) 2.25
Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med (1997) 2.24
Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.18
A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med (1998) 2.08
Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy (2011) 2.06
A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros (2012) 2.05
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med (2014) 1.96
Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol (2011) 1.92
High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem (2002) 1.89
In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med (2007) 1.82
Severed channels probe regulation of gating of cystic fibrosis transmembrane conductance regulator by its cytoplasmic domains. J Gen Physiol (2000) 1.81
Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med (2013) 1.81
S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells. Mol Pharmacol (2006) 1.79
The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel. J Biol Chem (2010) 1.76
Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med (2002) 1.75
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med (2007) 1.75
Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol (1997) 1.72
Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med (2001) 1.72
Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med (2010) 1.71
cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am J Physiol (1995) 1.69
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med (2014) 1.67
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med (2014) 1.64
Gating of the CFTR Cl- channel by ATP-driven nucleotide-binding domain dimerisation. J Physiol (2009) 1.58
CFTR activation: additive effects of stimulatory and inhibitory phosphorylation sites in the R domain. Am J Physiol (1997) 1.57
Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol (1999) 1.57
CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry (2006) 1.54
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest (2012) 1.53
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem (2009) 1.53
Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J (2008) 1.49
Glutathione permeability of CFTR. Am J Physiol (1998) 1.48
Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax (2015) 1.46
Adenosine triphosphate-dependent asymmetry of anion permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. J Gen Physiol (1998) 1.46
SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol (2009) 1.44
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med (2016) 1.43
Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells. Am J Physiol Cell Physiol (2003) 1.42
Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci (2005) 1.39
Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem (2006) 1.39
A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med (2000) 1.37
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem (2009) 1.36
Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc Natl Acad Sci U S A (1994) 1.34
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros (2014) 1.33
C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem (1999) 1.32
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell (2013) 1.29
The two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energetics. J Gen Physiol (2006) 1.28
Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol (1998) 1.27
Mechanism of chloride permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. Exp Physiol (2005) 1.26
Inhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator. FEBS Lett (1997) 1.24
The cytosolic termini of the beta- and gamma-ENaC subunits are involved in the functional interactions between cystic fibrosis transmembrane conductance regulator and epithelial sodium channel. J Biol Chem (2000) 1.23
Preferential phosphorylation of R-domain Serine 768 dampens activation of CFTR channels by PKA. J Gen Physiol (2005) 1.22
Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy (2014) 1.21
Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res (2001) 1.19
ENaC-CFTR interactions: the role of electrical coupling of ion fluxes explored in an epithelial cell model. Pflugers Arch (2002) 1.16
Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem (2004) 1.16
Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J (2008) 1.15
Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection. J Leukoc Biol (2012) 1.14
Phosphorylation of CFTR by PKA promotes binding of the regulatory domain. EMBO J (2005) 1.14
Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol (2014) 1.10
Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium. Laryngoscope (2011) 1.09
Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator. Autophagy (2012) 1.08
SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis. Am J Respir Cell Mol Biol (2005) 1.08
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol (2007) 1.08